EI
ARCT icon

EAM Investors’s Arcturus Therapeutics ARCT Stock Holding History

EAM Investors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-40,695
Closed -$1.9M – 274
2020
Q2 		$1.9M Buy
+40,695
New +$1.4M 0.42% 91
2020
Q1 		– Sell
-52,833
Closed -$574K – 214
2019
Q4 		$574K Sell
52,833
-10,807
-17% -$113K 0.13% 236
2019
Q3 		$654K Buy
+63,640
New +$688K 0.17% 215

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

EAM Investors's ARCT Position: Q3 2020 in Review

EAM Investors sold out of Arcturus Therapeutics (ARCT) in Q3 2020, closing a stake of 40,695 shares — an estimated $1.9M sold.

EAM Investors first reported a position in ARCT in Q3 2019 and held it in 3 quarters. The position peaked at $1.9M in Q2 2020. 127 funds tracked by Wall St. Rank hold ARCT as of Q3 2020.

  • EAM Investors reported no remaining Arcturus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • EAM Investors sold 40,695 Arcturus Therapeutics shares in Q3 2020, an estimated $1.9M.
  • EAM Investors first reported a position in Arcturus Therapeutics in Q3 2019 and held it in 3 quarters.
  • EAM Investors's Arcturus Therapeutics position peaked at $1.9M in Q2 2020.
  • 127 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.